Market closed

EyePoint Pharmaceuticals/$EYPT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Ticker

$EYPT
Trading on

Industry

Pharmaceuticals

Employees

121

EYPT Metrics

BasicAdvanced
$779M
Market cap
-
P/E ratio
-$2.04
EPS
1.52
Beta
-
Dividend rate
$779M
1.52
$30.99
$5.86
894K
5.504
5.209
10.022
10.612
-31.39%
-74.68%
12.321
2.72
2.72
-4.772
7.50%
-23.11%
12.01%
-3.17%

What the Analysts think about EYPT

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for EyePoint Pharmaceuticals stock.

EYPT Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

EYPT Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EYPT

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for EyePoint Pharmaceuticals stock?

EyePoint Pharmaceuticals (EYPT) has a market cap of $779M as of November 13, 2024.

What is the P/E ratio for EyePoint Pharmaceuticals stock?

The price to earnings (P/E) ratio for EyePoint Pharmaceuticals (EYPT) stock is 0 as of November 13, 2024.

Does EyePoint Pharmaceuticals stock pay dividends?

No, EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders as of November 13, 2024.

When is the next EyePoint Pharmaceuticals dividend payment date?

EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders.

What is the beta indicator for EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals (EYPT) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.